// Company Overview //
| Stock Name | 歐康維視生物 - B |
|---|---|
| Stock Code | 01477 |
| Company Full Name | 歐康維視生物 - B |
| Industry | 醫療保健 |
| Principal Activities | 為中國眼科醫藥平臺公司，從事開發及商業化眼科療法。 |
| Listing Date | 2020-07-10 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市靜安區石門一路211號旺旺大廈502-1室 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | http://www.ocumension.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Prospectus Date | 2020-06-29 |
|---|---|
| Offer Price | HK$ 14.66 / shares |
| Total Funds Raised | HK$ 776,466,900 |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
|---|
// First Day Performance
| First Day Close | Loading... |
|---|---|
| First Day Open | HK$ 43.0 |
| First Day Change | 152.39% |
| First Day Volume | 59068800.0 |
| First Day Turnover | 2394770000.0 |
// Price Chart //
Loading...
// Use of Proceeds
| Use of Proceeds | 1、約427.19百萬港元（即所得款項凈額的30.00%）將用于我們的核心產品OT401； 2、約711.98百萬港元（即所得款項凈額的50.00%）將用于其他候選藥物； 3、約142.40百萬港元（即所得款項凈額的10.00%）將用于根據我們與當地政府所訂合作協議收購蘇州的制造設施； 4、約142.40百萬港元（即所得款項凈額的10.00%）將用作營運資金及用于其他一般公司用途。 |
|---|
// Underwriting Syndicate //
联席保荐人 (2)
摩根士丹利亚洲有限公司
高盛（亚洲）有限责任公司
整体协调人 (3)
摩根士丹利亚洲有限公司
高盛（亚洲）有限责任公司
瑞银证券香港有限公司
联席账簿管理人 (3)
摩根士丹利亚洲有限公司
高盛（亚洲）有限责任公司
瑞银证券香港有限公司
联席牵头经办人 (3)
摩根士丹利亚洲有限公司
高盛（亚洲）有限责任公司
瑞银证券香港有限公司
// Cornerstone Investors //
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Alpha Profit Holdings Limited | 116,231,810 HKD | — | 7.48% | — | 6 months | 2021-01-10 |
| 2 | BlackRock Funds | 38,739,050 HKD | — | 2.49% | — | 6 months | 2021-01-10 |
| 3 | Boyu Capital Opportunities Master Fund | 38,739,050 HKD | — | 2.49% | — | 6 months | 2021-01-10 |
| 4 | Cormorant Asset Management, LP | 38,739,050 HKD | — | 2.49% | — | 6 months | 2021-01-10 |
| 5 | Fidelity International | 139,475,240 HKD | — | 8.98% | — | 6 months | 2021-01-10 |
| 6 | General Atlantic Singapore OT Pte. Ltd. | 77,485,430 HKD | — | 4.99% | — | 6 months | 2021-01-10 |
| 7 | HBM Healthcare Investments (Cayman) Ltd. | 23,243,430 HKD | — | 1.50% | — | 6 months | 2021-01-10 |
| 8 | Hudson Bay Master Fund LTD | 38,739,050 HKD | — | 2.49% | — | 6 months | 2021-01-10 |
| 9 | Lake Bleu Prime Healthcare Master Fund Limited | 54,242,000 HKD | — | 3.49% | — | 6 months | 2021-01-10 |
| 10 | Octagon Investments Master Fund LP | 15,495,620 HKD | — | 1.00% | — | 6 months | 2021-01-10 |
| 11 | OrbiMed Funds | 38,739,050 HKD | — | 2.49% | — | 6 months | 2021-01-10 |
| 12 | Rock Springs Capital Master Fund LP | 38,739,050 HKD | — | 2.49% | — | 6 months | 2021-01-10 |
| 13 | SCC Growth V Holdco L, Ltd. | 38,739,050 HKD | — | 2.49% | — | 6 months | 2021-01-10 |
| 14 | TLS Beta Pte. Ltd. | 77,485,430 HKD | — | 4.99% | — | 6 months | 2021-01-10 |
// Directors & Management //
| Chairman | 陳連勇 |
|---|---|
| Company Secretary | 阮添士;陳聽蟬 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 6 Dimensions Capital GP, LLC(18.90%);蘇州通和二期創業投資合伙企業(有限合伙)(13.23%);Boyu Capital Fund IV, L.P.(11.71%);淡馬錫控股(私人)有限公司(8.90%);The Capital Group Companies, Inc.(7.05%);蘇州通和毓承投資合伙企業(有限合伙)(5.67%) |
|---|
